Improvement in clinical outcomes4,5,9

Reduction in resource utilization6,7

Enhanced value in pharmacy benefit


reduction in # of hypoglycemic events for T1DM4

(<55 mg/dL; −0.38/24-h day; P<0.0001)


reduction in # of hypoglycemic events for T2DM5

(<55 mg/dL; −0.12/24-h day; P=0.0017)


average reduction in HbA1c9

(at 2-4 months; 95% CI, −0.70% to −0.39%)


reduction in # of diabetes-related hospital admissions7

[over 12 months (P<0.05)]


fewer hospital admissions due to hypoglycemia and/or DKA6


Advantages of pharmacy benefit

List Icon Image

Operational efficiencies

List Icon Image

Cost savings in removal of manual prior authorizations

List Icon Image

Utilization management and insights

Diabetes patient holds and discusses FreeStyle Libre reader with doctor

Highlights of clinical guidelines for the use of CGM

Several clinical organizations including the ADA, AACE, and ACE have published guidelines for the use of CGM in the management of diabetes.10,11 Highlights from the published guidelines are included below.

Collapse All Expand All

View highlights of clinical guidelines

American Diabetes Association (ADA)

The ADA published diabetes treatment guidelines as part of the 2020 Standards of Medical Care in Diabetes, making the following clinical and access recommendations specific to CGM:

  • CGMs, when used properly, together with insulin, are useful for lowering HbA1c and/or reducing hypoglycemia for people with type 1 diabetes and type 2 diabetes10,‡,§

  • CGM users should have access through third-party payers10

American Association of Clinical Endocrinologists (AACE) and American College of Endocrinology (ACE)

A 2019 consensus statement11 by the AACE and ACE on a comprehensive type 2 diabetes mellitus management algorithm describes the role of CGM, making the following clinical recommendations:

  • Patient's and clinician's understanding of glucose trends has been enhanced for people with T2D who use CGM

  • In helping patients better understand their glucose trends, CGM may also help with adherence

  • In providing real-time glucose data, CGM may support prevention of hypoglycemia

The role of CGM in reducing costs and complications

Collapse All Expand All

View NDC and HCPCS Codes

NDC Codes

  • 57599-0002-00: FreeStyle Libre 14 day reader

  • 57599-0001-01: FreeStyle Libre 14 day sensor

HCPCS Codes||,¶

For therapeutic CGM, use the following billing codes:

  • K0553: Supply allowance for therapeutic continuous glucose monitor (CGM), includes all supplies and accessories, 1 month supply = 1 unit of service12

  • K0554: Receiver (monitor), dedicated, for use with therapeutic glucose continuous monitor system12

  • KF modifier applies to Class III DME13
Phone and CGM FreeStyle Libre sensor and reader product image

Contact us

* (70-180 mg/dL)
Ɨ Data based on the number of patients assigned to each manufacturer based on last filled prescription in US Retail Pharmacy and DME.
ǂ Applicable to people with T1D who are not meeting glucose targets, are hypoglycemic unaware, and/or experience hypoglycemic episodes.
§ Applicable to people with T2D who are not meeting glucose targets.
|| Customer (including healthcare professionals and healthcare institutions) is ultimately responsible for determining the appropriate codes, coverage, and payment policies for individual patients.
¶ Abbott Diabetes Care (ADC) may not guarantee third-party coverage or payment for ADC products or reimburse customers (including healthcare professionals, healthcare institutions, consumers, and patients) for claims that are denied by third-party payers.
# Fingersticks are required for treatment decisions when you see Check Blood Glucose symbol, when symptoms do not match system readings, when you suspect readings may be inaccurate, or when you experience symptoms that may be due to high or low blood glucose.

References: 1. Battelino T, et al. [published online June 8, 2019]. Diabetes Care. 2019;42(8):1593-1603. 2. Beck RW, et al. Diabetes Care. 2019;42(3):400-405. 3. Lang J, et al. Expanded real-world use confirms strong association between frequency of flash glucose monitoring and glucose control. Diabetes Technol Ther. 2019;21(suppl 1):A-40. doi:10.1089/dia.2019.2525.abstracts 4. Bolinder J, et al. Lancet. 2016;388(10057):2254-2263. 5. Haak T, et al. Diabetes Ther. 2017;8(1):55-73. 6. Charleer S, et al. Diabetes Care. 2020;43(2):389-397. 7. Fokkert M, et al. BMJ Open Diabetes Res Care. 2019;7(1):e000809. doi:10.1136/bmjdrc-2019-000809 8. Kerr M, et al. CGM use associated with reduction in acute diabetes complications, even in patients using less than four test strips per day. Diabetes Technol Ther. 2020;22(suppl 1):A-55. doi:10.1089/dia.2020.2525.abstracts 9. Evans M, et al. [published online October 31, 2019]. Diabetes Ther. 2020;11:83-95. doi:10.1007/s13300-019-00720-0 10. American Diabetes Association. Diabetes Care. 2020;43(suppl 1):S77-S88. 11. Garber AJ, et al. Endocr Pract. 2019;25(1):69-100. 12. Centers for Medicare & Medicaid Services. Home blood glucose monitors. Medicare National Coverage Determinations Manual.  CMS publication 100-03, chap 1, sec 40.2. Published February 15, 2019. Accessed April 3, 2020. https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/Internet-Only-Manuals-IOMs-Items/CMS014961 13. Centers for Medicare & Medicaid Services. Medicare Claims Processing. CMS publication 100-04. Published June 28, 2019. Accessed April 3, 2020. https://www.cms.gov/Regulations-and-Guidance/Guidance/Transmittals/2019Downloads/R4328CP.pdf.

ADC-17130 v2.0 07/20

Indications and Important Safety Information

FreeStyle Libre 14 day system: The FreeStyle Libre 14 day Flash Glucose Monitoring System is a continuous glucose monitoring (CGM) device indicated for the management of diabetes in persons age 18 and older. It is designed to replace blood glucose testing for diabetes treatment decisions. The System detects trends and tracks patterns aiding in the detection of episodes of hyperglycemia and hypoglycemia, facilitating both acute and long-term therapy adjustments. Interpretation of the System readings should be based on the glucose trends and several sequential readings over time. The System is intended for single patient use and requires a prescription.

CONTRAINDICATIONS: Remove the sensor before MRI, CT scan, X-ray, or diathermy treatment.

WARNINGS/LIMITATIONS: Do not ignore symptoms that may be due to low or high blood glucose, hypoglycemic unawareness, or dehydration. Check sensor glucose readings with a blood glucose meter when Check Blood Glucose symbol appears, when symptoms do not match system readings, or when readings are suspected to be inaccurate. The FreeStyle Libre 14 day system does not have alarms unless the sensor is scanned, and the system contains small parts that may be dangerous if swallowed. The FreeStyle Libre 14 day system is not approved for pregnant women, persons on dialysis, or critically-ill population. Sensor placement is not approved for sites other than the back of the arm and standard precautions for transmission of blood borne pathogens should be taken. The built-in blood glucose meter is not for use on dehydrated, hypotensive, in shock, hyperglycemic-hyperosmolar state, with or without ketosis, neonates, critically-ill patients, or for diagnosis or screening of diabetes. When using FreeStyle LibreLink app, access to a blood glucose monitoring system is required as the app does not provide one. Review all product information before use or contact Abbott Toll Free (855-632-8658) or visit www.freestylelibre.us for detailed indications for use and safety information. For full indications for use and safety information, see more here.

FreeStyle Libre 2 system: The FreeStyle Libre 2 Flash Glucose Monitoring System is a continuous glucose monitoring (CGM) device with real time alarms capability indicated for the management of diabetes in persons age 4 and older.*

WARNINGS/LIMITATIONS*: The System must not be used with automated insulin dosing (AID) systems, including closed loop and insulin suspend systems. Remove the sensor before MRI, CT scan, X-ray, or diathermy treatment. Do not take high doses of vitamin C (more than 500 mg per day), as this may falsely raise your Sensor readings. Failure to use the System according to the instructions for use may result in missing a severe low blood glucose or high blood glucose event and/or making a treatment decision that may result in injury. If glucose alarms and readings from the System do not match symptoms or expectations, use a fingerstick blood glucose value to make diabetes treatment decisions. Seek medical attention when appropriate and contact Abbott Toll Free (855-632-8658) or visit * www.freestylelibre.us for detailed indications for use and safety information.

* Please refer to www.freestylelibre.us for the indications and important safety information.

The shape of the circle sensor unit, FreeStyle, Libre, and related brand marks are owned by Abbott. Other trademarks are the property of their respective owners.

No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott Laboratories, except to identify the product or services of the company. Product images are for illustrative purposes only.

ADC-25347 v2.0 09/20